Alliance Pharma PLC Annual Report and Notice of AGM (3729W)

TIDMAPH

RNS Number : 3729W

Alliance Pharma PLC

16 April 2019

 
                                              16 April 2019 
 

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Annual Report & Accounts and Notice of AGM

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that the following documents are now available on the Company's website, www.alliancepharmaceuticals.com:

   --      The Annual Report & Accounts for the year ended 31 December 2018 

-- The Notice of the 2019 Annual General Meeting ("AGM"), which will be held at 10.00am on 23 May 2019 at the offices of Buchanan, 107 Cheapside, London EC2V 6DN

Printed copies of all the documents have been posted to those shareholders who have opted out of receiving electronic communications from the Company.

Printed copies of the documents are also available by contacting Buchanan by email at [e-mail] or by telephoning Buchanan on 020 7466 5000.

For further information:

 
 Alliance Pharma plc                          + 44 (0)1249 466966 
 Peter Butterfield, Chief Executive 
  Officer 
 Andrew Franklin, Chief Financial Officer 
 www.alliancepharma.co.uk 
 Buchanan                                    + 44 (0)20 7466 5000 
 Mark Court / Sophie Wills / Hannah 
  Ratcliff 
 
 Numis Securities Limited                    + 44 (0)20 7260 1000 
 Nominated Adviser: Freddie Barnfield 
 Corporate Broking: James Black 
 
 
 Investec Bank plc                    + 44 (0)20 7597 5970 
 Corporate Finance: Daniel Adams / 
  Ed Thomas 
 Corporate Broking: Patrick Robb / 
  Tejas Padalkar 
 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with affiliate offices in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We currently own or license the rights to more than 90 pharmaceutical and consumer healthcare products, which are managed on a portfolio basis according to their growth potential. Promotional investment is focussed on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.

Our tried and tested 'Buy and Build' strategy, allows us to benefit both from organic growth opportunities and from enhancing our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCIFMMTMBABBLL

(END) Dow Jones Newswires

April 16, 2019 07:05 ET (11:05 GMT)